J Korean Med Sci.  2011 Jul;26(7):945-950. 10.3346/jkms.2011.26.7.945.

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation

• Han SJ
• Kim HS
• Kim KI
• Whang SM
• Hong KS
• Lee WK
• Lee SH

• KMID: 1094268
• DOI: http://doi.org/10.3346/jkms.2011.26.7.945

Abstract

Although the incidence of bleeding complications during extracorporeal membrane oxygenator (ECMO) support has decreased in various trials, bleeding is still the most fatal complication. We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure. We assessed 73 consecutive patients who received ECMO due to acute cardiac or respiratory failure between January 2006 and December 2009. To evaluate the efficacy of nafamostat mesilate, we divided the patients into 2 groups according to the anticoagulants used during ECMO support. All patients of nafamostat mesilate group were male with a mean age of 49.2 yr. Six, 3, 5, and 3 patients were diagnosed with acute myocardial infarction, cardiac arrest, septic shock, and acute respiratory distress syndrome, respectively. The mean dosage of nafamostat mesilate was 0.64 mg/kg/hr, and the mean duration of ECMO was 270.7 hr. The daily volume of transfused packed red blood cells, fresh frozen plasma, and cryoprecipitate and the number of complications related to hemorrhage and thrombosis was lower in the nafamostat mesilate group than in the heparin group. Nafamostat mesilate should be considered as an alternative anticoagulant to heparin to reduce bleeding complications during ECMO.

Keyword

Extracorporeal Membrane Oxygenation; Anticoagulants; Heparin; Nafamostat; Complications; Intensive Care

MeSH Terms

Acute Disease
Anticoagulants/*administration & dosage
Dose-Response Relationship, Drug
*Extracorporeal Membrane Oxygenation
Female
Guanidines/*administration & dosage
Heart Failure/diagnosis/mortality/therapy
Heparin/administration & dosage
Humans
Male
Middle Aged
Myocardial Infarction/diagnosis/mortality/therapy
Respiratory Distress Syndrome, Adult/diagnosis/mortality/therapy
Retrospective Studies
Shock, Septic/diagnosis/mortality/therapy
Survival Analysis

Reference

1. Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol. 2010. 76:534–540.

2. von Segesser LK, Turina M. Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators. J Thorac Cardiovasc Surg. 1989. 98:386–396.

3. Teng CL, Kim JS, Port FK, Wakefield TW, Till GO, Yang VC. A protamine filter for extracorporeal blood heparin removal. ASAIO Trans. 1988. 34:743–746.

4. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol. 2006. 28:4–10.

5. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, Kitamura N. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol. 1991. 93:215–217.

6. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron. 1993. 64:376–381.

7. Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, Choi SO. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. Ren Fail. 2009. 31:668–675.

8. Nagaya M, Futamura M, Kato J, Niimi N, Fukuta S. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report. J Pediatr Surg. 1997. 32:531–535.

9. Ota T, Okada K, Kano H, Okita Y. Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage. Interact Cardiovasc Thorac Surg. 2007. 6:270–273.

10. Daimon S, Umeda T, Michishita I, Wakasugi H, Genda A, Koni I. Goodpasture's-like syndrome and effect of extracorporeal membrane oxygenator support. Intern Med. 1994. 33:569–573.

11. Kotani K, Ichiba S, Andou M, Sano Y, Date H, Tedoriya T, Goto K, Shimizu N. Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation. J Thorac Cardiovasc Surg. 2002. 124:626–627.

12. Hong WK, Kim GW, Lee SH, Lee WJ, Yoon DH, Kim HS, Han SJ. A case involving the use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation in acute myocardial infarction. Korean J Med. 2010. 79:181–186.

13. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis. 1985. 15:164–168.

14. Fuse I, Higuchi W, Toba K, Aizawa Y. Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets. 1999. 10:212–218.

15. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta. 1981. 661:342–345.

16. Takahama T, Kanai F, Hiraishi M, Onishi K, Yamazaki Z, Furuse A, Asano K, Yoshitake T, Kazama M. Application of a prostacyclin analogue (PG) and protease inhibitor (FUT) as anticoagulants with an LVAD system. ASAIO Trans. 1986. 32:253–257.

17. Martindale SJ, Shayevitz JR, D'Errico C. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery. J Cardiothorac Vasc Anesth. 1996. 10:458–463.

18. Baird CW, Zurakowski D, Robinson B, Gandhi S, Burdis-Koch L, Tamblyn J, Munoz R, Fortich K, Pigula FA. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg. 2007. 83:912–919.

19. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth. 2009. 13:154–175.

20. Ang AL, Teo D, Lim CH, Leou KK, Tien SL, Koh MB. Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation - a single centre experience. Vox Sang. 2009. 96:34–43.

21. Formica F, Avalli L, Colagrande L, Ferro O, Greco G, Maggioni E, Paolini G. Extracorporeal membrane oxygenation to support adult patients with cardiac failure: predictive factors of 30-day mortality. Interact Cardiovasc Thorac Surg. 2010. 10:721–726.

22. Bakhtiary F, Keller H, Dogan S, Dzemali O, Oezaslan F, Meininger D, Ackermann H, Zwissler B, Kleine P, Moritz A. Venoarterial extracorporeal membrane oxygenation for treatment of cardiogenic shock: clinical experiences in 45 adult patients. J Thorac Cardiovasc Surg. 2008. 135:382–388.

23. Liden H, Wiklund L, Haraldsson A, Berglin E, Hultman J, Dellgren G. Temporary circulatory support with extra corporeal membrane oxygenation in adults with refractory cardiogenic shock. Scand Cardiovasc J. 2009. 43:226–232.

24. Sung K, Lee YT, Park PW, Park KH, Jun TG, Yang JH, Ha YK. Improved survival after cardiac arrest using emergent autopriming percutaneous cardiopulmonary support. Ann Thorac Surg. 2006. 82:651–656.

25. Nehra D, Goldstein AM, Doody DP, Ryan DP, Chang Y, Masiakos PT. Extracorporeal membrane oxygenation for nonneonatal acute respiratory failure: the Massachusetts General Hospital experience from 1990 to 2008. Arch Surg. 2009. 144:427–432.

26. Combes A, Leprince P, Luyt CE, Bonnet N, Trouillet JL, Léger P, Pavie A, Chastre J. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation for refractory cardiogenic shock. Crit Care Med. 2008. 36:1404–1411.

27. Chen JS, Ko WJ, Yu HY, Lai LP, Huang SC, Chi NH, Tsai CH, Wang SS, Lin FY, Chen YS. Analysis of the outcome for patients experiencing myocardial infarction and cardiopulmonary resuscitation refractory to conventional therapies necessitating extracorporeal life support rescue. Crit Care Med. 2006. 34:950–957.

28. Schwertz H, Carter JM, Russ M, Schubert S, Schlitt A, Buerke U, Schmidt M, Hillen H, Werdan K, Buerke M. Serine protease inhibitor nafamostat given before reperfusion reduces inflammatory myocardial injury by complement and neutrophil inhibition. J Cardiovasc Pharmacol. 2008. 52:151–160.